Priming in the brain, an immunologically privileged organ, elicits anti‐tumor immunity

A crucial question in the study of tumor neuro‐immunology concerns the capacity of the central nervous system to initiate and execute an immune response. In a 100% fatal rat malignant glioma model, genetically modified tumors secreting INF‐γ intracerebrally generate an immune response resulting in a...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of cancer Vol. 75; no. 2; pp. 266 - 276
Main Authors Fathallah‐Shaykh, Hassan M., Gao, Wei, Cho, Michael, Herrera, Maria Alejandra
Format Journal Article
LanguageEnglish
Published New York Wiley Subscription Services, Inc., A Wiley Company 19.01.1998
Wiley-Liss
Subjects
Animal tumors. Experimental tumors
Animals
Biological and medical sciences
Brain - immunology
Brain Neoplasms - immunology
Cancer Vaccines - immunology
Experimental nervous system tumors
Glioma - immunology
Humans
Immunization
Interferon-gamma - physiology
Interleukin-2 - physiology
Medical sciences
Neoplasm Transplantation
Rats
Rats, Inbred F344
Tumors
Intracranial
Animal model
Nervous system diseases
Immune response
Rat
Priming effect
Cytokine
Rodentia
Vaccine
Malignant tumor
Cerebral disorder
Malignant glioma
Vertebrata
Mammalia
Interleukin 2
Animal
Central nervous system disease
Genetic engineering
Gamma interferon
Online AccessGet full text

Cover

More Information
Summary:A crucial question in the study of tumor neuro‐immunology concerns the capacity of the central nervous system to initiate and execute an immune response. In a 100% fatal rat malignant glioma model, genetically modified tumors secreting INF‐γ intracerebrally generate an immune response resulting in a substantial increase in survival time, tumor rejection and specific systemic immunity. Tumors modified to secrete IL‐2 alone do not change the biologic behavior of transfected gliomas. INF‐γ induces elevated expression of major‐histocompatibility‐complex‐class‐I and ‐class‐II molecules in microglia throughout the brain and invokes enhanced tumor infiltration by CD4, CD8 and NK cells. These findings demonstrate successful immunization against a central‐nervous‐system tumor by direct priming in the brain with a live growth‐competent tumor vaccine. Int. J. Cancer 75:266–276, 1998. © 1998 Wiley‐Liss, Inc.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0020-7136
1097-0215
DOI:10.1002/(SICI)1097-0215(19980119)75:2<266::AID-IJC16>3.0.CO;2-B